Remove 2019 Remove Drug Development Remove Medical Records
article thumbnail

Can Hepatitis C drugs reduce symptoms of PTSD?

European Pharmaceutical Review

A study led by Boston University School of Public Health (BUSPH) and the White River Junction Veterans Affairs Medical Center in Vermont has completed a rigorous analysis to compare the effectiveness of direct acting antivirals on improving symptoms of posttraumatic stress disorder (PTSD). .

article thumbnail

Long-Awaited Guidance on FDAMA 115: Confirmatory Evidence Finally Has Its Moment (to be Crossed Off the FDA’s Guidance To-Do List)

FDA Law Blog: Biosimilars

Two weeks ago, FDA published a draft of its latest drug development guidance explaining how drug and biological product developers can use this pathway to meet the statutory standard for efficacy. We are heartened to see that this latest guidance reflects many of the advances we observed in practice since 2019.

article thumbnail

Deep 6 AI: the smart software breathing new life into clinical trials

pharmaphorum

Patient recruitment and retention in clinical trials have long been significant challenges for drug developers. As a result, trawling through a physician’s notes in electronic medical records (EMRs), pathology reports, and other medical data to determine the most important insights could take human beings months.